We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NOW:NYSEServiceNow, Inc. Analysis

Data as of 2026-06-30 - not real-time

$99.97

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

ServiceNow delivers a compelling growth narrative with 22% year‑over‑year revenue growth, a robust 76% gross margin and an expanding profit profile (12.6% net margin). Forward earnings are projected to surge to $5.03 per share, compressing the forward P/E to ~20x versus a trailing P/E of 59x and an industry average of 37x. The discounted cash‑flow model places intrinsic value near $165, implying a ~41% upside from the current $99.97 price, while the balance sheet remains strong with net cash of roughly $2.8 B and a low debt‑to‑equity of 20.7%.
On the technical side, the stock trades below its 20‑day SMA (105.6) and the MACD has turned bearish, with decreasing volume and an elevated 30‑day volatility of 83%. Recent AI‑governance and IBM collaborations could catalyze future top‑line growth, but short‑term price pressure remains as the market digests these announcements. Overall, the fundamentals and valuation suggest a buying opportunity, while near‑term technical weakness tempers immediate optimism.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below 20‑day SMA
  • Decreasing volume and high short‑term volatility
  • Current price still above immediate support level

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Projected earnings acceleration and forward P/E ~20x
  • DCF‑derived upside of ~41% and strong cash position
  • Strategic AI and IBM partnerships expanding addressable market

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Recurring subscription model with high gross margins
  • Sustained revenue growth and solid ROE (~16%)
  • Long‑term intrinsic value gap and low beta indicating defensive profile

Key Metrics & Analysis

Financial Health

Revenue Growth22.10%
Profit Margin12.59%
P/E Ratio59.5
ROE16.07%
ROA5.66%
Debt/Equity20.73
P/B Ratio8.8
Op. Cash Flow$5.4B
Free Cash Flow$5.1B
Industry P/E36.9

Technical Analysis

TrendNeutral
RSI48.8
Support$89.39
Resistance$139.20
MA 20$105.61
MA 50$99.85
MA 200$134.10
MACDBearish
VolumeDecreasing
Fear & Greed Index90.09

Valuation

Fair Value$165.44
Target Price$141.48
Upside/Downside41.52%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.73
Volatility83.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.